TG Therapeutics (NASDAQ:TGTX) Downgraded by StockNews.com to Sell

TG Therapeutics (NASDAQ:TGTX) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Sunday.

TGTX has been the subject of several other reports. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright raised their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Up 4.0 %

NASDAQ:TGTX opened at $32.20 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The stock has a market cap of $5.01 billion, a P/E ratio of -321.97 and a beta of 2.25. The stock has a 50-day simple moving average of $29.62 and a 200-day simple moving average of $23.91.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue was down 49.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS. As a group, analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at $35,000. Blue Trust Inc. grew its position in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares during the period. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics in the 3rd quarter worth about $53,000. Finally, Values First Advisors Inc. purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.